Research programme: anti-EphA2 antibodies - Atreca
Latest Information Update: 28 May 2021
At a glance
- Originator Atreca
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 20 May 2021 Anti-EphA2 antibodies are available for licensing as of 20 May 2021. https://www.atreca.com/partnering/ ((Atreca website, May 2021)
- 13 May 2021 Preclinical trials in Cancer in USA (Parenteral) before May 2021
- 30 Apr 2021 The United States Patent and Trademark Office issues a Notice of Allowance for US patent application of Atreca’s Immune Repertoire Capture® technology